Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?
AuthorsKavanagh, Dara O
Barry, Kevin M
Waldron, Ronan P
Eustace, Paul W
AffiliationDepartment of Surgery, Mayo General Hospital, Castlebar, Co Mayo, Ireland., firstname.lastname@example.org
Aged, 80 and over
*Gene Expression Regulation, Neoplastic
MetadataShow full item record
CitationBMC Cancer. 2009 Jan 1;9:1.
AbstractBACKGROUND: The development of novel chemotherapeutic agents in colorectal cancer has improved survival. Following initial response to chemotherapeutic strategies many patients develop refractory disease. This poses a significant challenge common to many cancer subtypes. Newer agents such as Bevacizumab have successfully targeted the tyrosine kinase receptor epidermal growth factor receptor in metastatic colorectal cancer. Human epidermal growth factor receptor-2 is another member of the tyrosine kinase receptor family which has been successfully targeted in breast cancer. This may play a role in colorectal cancer. We conducted a clinicopathological study to determine if overexpression of human epidermal growth factor receptor-2 is a predictor of outcome in a cohort of patients with colorectal cancer. METHODS: Clinicopathological data and paraffin-embedded specimens were collected on 132 consecutive patients who underwent colorectal resections over a 24-month period at Mayo General Hospital. Twenty-six contained non-malignant disease. Her-2/neu protein overexpression was detected using immunohistochemistry (IHC). The HER-2 4B5 Ventana monoclonal antibody was used. Fluorescent insitu hybridisation (FISH) was performed using INFORM HER-2/Neu Plus. Results were correlated with established clinical and pathological predictors of outcome including TNM stage. Statistical analysis was performed using SPSS version 11.5. RESULTS: 114 were HER-2/Neu negative using IHC, 7 showed barely perceptible positivity (1+), 9 showed moderate staining (2+) and 2 were strongly positive (3+). There was no correlation with gender, age, grade, Dukes' stage, TNM stage, time to recurrence and 5-year survival (p > 0.05). FISH was applied to all 2+ and 3+ cases as well as some negative cases selected at random. Three were amplified (2 were 3+ and 1 was 2+). Similarly, HER-2 gene overexpression did not correlate with established prognostic indicators. CONCLUSION: HER-2 protein is over expressed in 11% of colorectal cancer patients. The gene encoding HER-2 is amplified in 3% of cases. Overexpression of HER-2 is not a predictor of outcome. However, patients who over express HER-2 may respond to Herceptin therapy.
- HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.
- Authors: Liu W, Zhong S, Chen J, Yu Y
- Issue date: 2012 Apr
- Her-2/neu over-expression correlates with more advanced disease in Iranian colorectal cancer patients.
- Authors: Tavangar SM, Shariftabrizi A, Soroush AR
- Issue date: 2005 Mar
- Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan.
- Authors: Li JW, Chuang TC, Yang AH, Hsu CK, Kao MC
- Issue date: 2005 Apr
- Human epidermal growth factor receptor-2 family in colorectal adenocarcinoma: correlation with survival and clinicopathological findings.
- Authors: Molaei M, Pejhan S, Nayer BN, Moradi A, Ghiasi S, Zali MR
- Issue date: 2009 Mar
- HER 2/neu protein expression in colorectal cancer.
- Authors: Schuell B, Gruenberger T, Scheithauer W, Zielinski Ch, Wrba F
- Issue date: 2006 May 8